Canagliflozin Reduces Gout Flares in T2D Patients
According to a study, canagliflozin was superior to placebo in reducing serum urate concentration in type 2 diabetes (T2D) patients with a history of...
Wearable Sweat Sensor Shows Promise in Detecting Gout Biomarkers and More
Researchers have recently found that a wearable sensor can monitor the levels of metabolites and nutrients present in a person’s blood by analyzing sweat....
Rheum in Review: Does CBD Help Arthritis?, Gout Patients Have More Comorbidities, Alternative to...
Research on marijuana and/or cannabidiol (CBD) as a medical treatment may be limited, but that doesn’t stop arthritis patients from giving it a try.
Rheum Roundup: CBD and THC in Rheumatic Disease, Gout Mortality, RA Disability
Researchers have recently undertaken a double-blinded, randomized, placebo-controlled trial of the efficacy of cannabidiol (CBD) followed by tetrahydrocannabinol (THC)
Mortality Risk Higher Among Gout Patients
Compared to the general population, patients with gout have more comorbidities—aside from cardiovascular (CV) diseases—and a greater risk of death, according to a recent study.
Gout Flares Are Common, Even with Allopurinol Use
A recent study published in Arthritis Research & Therapy evaluated the frequency of flares in gout patients and the association between flares and use of allopurinol.
Rheum Roundup: Secukinumab Safety, SCOTUS on Osteoporosis Drug, Opioids May Worsen TJA Outcomes, and...
Secukinumab (Cosentyx), a human immunoglobulin G1-kappa monoclonal antibody that inhibits interleukin-17A, is a safe long-term treatment option for patients with moderate-to-severe plaque psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
